First-line treatment for extensive-stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of two immunotherapy drugs plus chemotherapy as the first treatment for extensive-stage small cell lung cancer. It aims to see if this combination is safe and works better than standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have extensive-stage small cell lung cancer (cancer that has spread beyond one lung).
- You have not had any prior treatment for this cancer.
- Your doctors expect you to live at least 3 more months.
- You are physically active and able to take care of yourself (ECOG score 0 or 1).
- Your organs (like blood, liver, kidneys, heart) are working well enough, based on blood tests and heart check.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two experimental immunotherapy drugs (ivonescimab and cadonilimab) with standard chemotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination works better than chemo alone.
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
This trial tests a new combination of drugs, including liposomal irinotecan, as the first treatment for extensive-stage small cell lung cancer. It aims to see if this combination can help control the cancer better than standard options.
This trial tests a combination of an immunotherapy drug (adebrelimab), chemotherapy, and radiation therapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if this combination helps people live longer and feel better.
This trial tests a new combination of immunotherapy (adebrelimab) with chemotherapy and radiation as the first treatment for extensive-stage small-cell lung cancer. It aims to see if this approach can help control the cancer better than standard treatments.
This study tests a new combination treatment for extensive-stage small cell lung cancer. You would receive an immunotherapy drug (adebrelimab) together with chemotherapy and a very low dose of chest radiation, to see if this helps control the cancer better.
Hear when a new Adebrelimab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.